12/3
01:00 am
ipsey
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Low
Report
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
11/18
01:00 am
ipsey
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Neutral
Report
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
11/15
11:00 am
ipsey
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Neutral
Report
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
10/23
01:00 am
ipsey
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
Low
Report
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance